Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2019 May 9;17(13):2776–2784.e4. doi: 10.1016/j.cgh.2019.04.061

Figure 1. Cumulative incidence of advanced fibrosis1 with long-term daily aspirin use2, among patients with baseline early-stage NAFLD* (n=317).

Figure 1.

Abbreviations: NAFLD, nonalcoholic fatty liver disease; No., number

1Incident advanced fibrosis was defined by the first recorded Fibrosis-4 (FIB-4) score > 2.67 or NAFLD Fibrosis Score (NFS) > 0.67, or aspartate aminotransferase-to-platelet ratio index (APRI) > 1.0 during study follow-up. Follow-up measurements of each index score was obtained at least annually in all included participants.

2Daily aspirin use was ascertained and verified by trained study staff at enrollment and at each clinical visit. Non-regular aspirin use was defined as less than daily use or non-use of aspirin. This variable was prospectively-updated during study follow-up and modeled as a time-varying exposure..

*Early-stage NAFLD defined as baseline fibrosis stage 0-2 on enrollment liver biopsy, confirmed by a blinded pathologist.